MedCity News

AUGUST 7, 2023

Vistagen’s stock price rocketed skyward on the results, which support progression to another Phase 3 study. Vistagen Therapeutics’ fast-acting nasal spray drug, fasedienol, hit primary and secondary goals of an abbreviated late-stage study in social anxiety disorder.

Biopharma 98

Biopharma Pharma 98

PM360

DECEMBER 20, 2023

General hospitals, which is classified to Grade 3, have the highest capability of treatment and medical resources. These medicines are considered essential because they meet key public health needs and tend to have low prices. Category 2 consists of medicines that are alternatives to the ones in Category 1 but have a higher price.

Marketing 105

Marketing Insurance Medical Manufacturing 105

World of DTC Marketing

SEPTEMBER 23, 2021

The suggestion by Pfizer’s CEO that drug pricing negotiations with the government would slow innovation is PR doubletalk. When we asked you to rapidly expand manufacturing so we can produce 3, 4 billion doses per year, you did it,” Bourla said. trillion social spending package. Then there is the tale of Biogen.

Pharma 214

Pharma Government Prescription Education 214

MedCity News

DECEMBER 15, 2022

The volume of price transparency data that hospitals must disclose online amounts to about 3 terabytes — compared to the whopping 630 terabytes of data that payers have been tasked with posting. Payers and providers face different challenges when it comes to compliance.

Healthcare 112

Healthcare Healthcare 112

PM360

OCTOBER 25, 2023

In this article, we discuss the challenges and opportunities within the current landscape and key issues impacting pricing and access for combination therapy. Combinations may present in a number of possible permutations, including purely novel components, components with established indications and prices, and generic/biosimilar components.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Marketing Pharmaceutical manufacturing 105

PM360

NOVEMBER 27, 2023

In this article, we investigate strategies that manufacturers could consider to optimize pricing and access opportunities for their combinations in today’s environment. Status Quo: The Core Issue In oncology, it has been the “status quo” for combination therapies to face challenges with respect to pricing and access.

Manufacturing 111

Manufacturing Marketing Competition Patients 111

The Brooks Group

MARCH 11, 2014

If you're looking for ways to make sure your team is selling at premium prices, share these principles with them ASAP. Rule #1 For Selling At Premium Prices: *The Rule of Credibility*. And that prospect has got to believe that you believe that you’re going to get that price. She asks the price. This leads me to Rule #3.

Prospecting 40

Prospecting Sales Leads Food 40

World of DTC Marketing

SEPTEMBER 9, 2021

SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. Generally, healthcare prices are higher in the U.S. healthcare spending will reach $6.2 healthcare. healthcare spending.

Healthcare 222

Healthcare Healthcare Government Insurance 222

MedCity News

AUGUST 21, 2022

employers is more than double the 3% increase employers experienced in 2022, the report said. increase in the Consumer Price Index. increase in average costs for U.S. However, the increase is below the 9.1%

Healthcare 104

Healthcare Healthcare 104

World of DTC Marketing

MARCH 28, 2022

Worldwide, alcohol is responsible for an estimated 3 million deaths each year, with over 400,000 from cancer. Insurance companies should give price incentives to employers to execute wellness programs within their companies. The question is will the healthcare community do anything about these findings?

Insurance 249

Insurance Ethics Healthcare Healthcare 249

World of DTC Marketing

MAY 26, 2021

The Committee’s investigation uncovered the following key findings: Uninhibited Price Increases: Since launching Humira in 2003, AbbVie (and its predecessor company Abbott Laboratories) have raised the drug’s price 27 times, including by nearly 30% in one 10-month period. net revenue from Humira. AbbVie’s yearly U.S. billion in 2020.

Competition 180

Competition Marketing Government Patients 180

Healthcare Success

APRIL 8, 2024

The Benefits of a 7P Approach to Marketing The fundamental purpose of marketing is to place the right product in the right place, at the right price and time, and to fulfill the consumer's needs. Price Price is just that, what you charge and what your customers pay. Pricing structures. What Are the 7 Ps of Marketing?

Marketing 112

Marketing Competition Patients Healthcare 112

World of DTC Marketing

JANUARY 24, 2022

A study in 2020 estimated that the median cost of getting a new drug into the market was $985 million, and the average price was $1.3 ” VCs also don’t like price controls. 3, known as the Lower Drug Costs Now Act. “But they’ll disappear if Congress passes these price controls. Only about $2.2

FDA 225

FDA Marketing Medicine Government 225

pharmaphorum

DECEMBER 6, 2023

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling the end of the programme and wreaking havoc with its share price.

52

52

pharmaphorum

NOVEMBER 21, 2022

Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been predicted by industry observers. The post Provention prices type 1 diabetes drug Tzield at $194,000 appeared first on.

Insurance 113

Insurance Sales Patients Marketing 113

PM360

JULY 26, 2023

Since passage of the Inflation Reduction Act (IRA) in August 2022, the focus of many industry analysts and pharmaceutical companies has been on two important first order concerns: identifying products to be negotiated by the Centers for Medicare & Medicaid Services (CMS) and assessing the direct impact on prices.

Manufacturing 98

Manufacturing Pharma Competition Distribution 98

World of DTC Marketing

MAY 4, 2022

A 2015 Commonwealth Fund brie f showed that — before the major provisions of the Affordable Care Act were introduced — the United States had worse outcomes and spent more on health care, primarily because of greater use of medical technology and higher prices, compared to other high-income countries.

Healthcare 210

Healthcare Healthcare Doctors Insurance 210

World of DTC Marketing

JANUARY 8, 2021

According to ars technica “award judges cited Moderna’s pricing of its COVID-19 vaccine, which was developed with $1 billion in federal funding. Still, despite the tax-payer backing, Moderna set the estimated prices for its vaccine significantly higher than other vaccine developers.”

Government 266

Government Safety FDA Pharma 266

pharmaphorum

DECEMBER 7, 2022

Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Life Sciences Practice team explores in greater depth the situation for these orphan drugs in France in this final article of a three-part series.

Patients 90

Patients Manufacturing Consulting Marketing 90

pharmaphorum

DECEMBER 9, 2022

There was also encouraging safety data observed within a wider group of 92 patients: 3% of patients experienced Grade 3 or higher cytokine release syndrome (CRS) and 8% experienced Grade 3 or higher immune effector cell-associated neurotoxicity syndrome (ICANS). months) to the data observed in the prior ALLCAR19 study.

Food and Drug Administration 85

Food and Drug Administration Safety Biopharma Patients 85

pharmaphorum

JANUARY 27, 2023

Energy costs are critical and the impact in 2023 is likely to be substantially greater than last year, even if actual prices level out: companies who hedged against short-term price rises in 2022 are unlikely to have the same level of financial cover in the mid to longer term. Governments will act, but will it be enough?

Medicine 89

Medicine Government Marketing Transportation 89

pharmaphorum

SEPTEMBER 6, 2022

NICE has said it is unable to recommend NHS use of AstraZeneca’s Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker. The post NICE says no to Lynparza in prostate cancer, creating UK access divide appeared first on.

Manufacturing 110

Manufacturing Patients Marketing 110

pharmaphorum

JULY 4, 2022

Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndrome (SBS), although its share price remains under pressure. It had cash, cash equivalents, and short-term investments of $37 million as of 31 March 31.

Biopharma 87

Biopharma Leads Food Safety 87

Pharmaceutical Technology

NOVEMBER 9, 2022

Despite their potential multi-million-dollar sticker price, if haemophilia treatments by BioMarin and CSL Behring prove durable, they could help patients save money compared to current treatments, experts note. A previous October 2020 report concluded that longer-term safety and efficacy were needed to update health-benefit price benchmarks.

Safety 111

Safety Pharmaceutical Patients Medicine 111

pharmaphorum

OCTOBER 3, 2022

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day set at a list price of $158,000 per year in the US, sparking outcry. ALS affects over 30,000 people in the US.

Insurance 52

Insurance Prescription FDA Patients 52

Pharmaceutical Technology

NOVEMBER 3, 2022

A Quantitative View on Award Criteria in Tenders in the EU5 from 2011 to 2020 , Genane C, Trenti S In-Person and Virtual Poster Session 3 Date: Tuesday 8 November 2022 Poster Session Time: 10:00–13:15 HPR150: P&R Policies and Macro-Trends Pertinent to CGTs: Where Are the Main Barriers and Who Leads the Efforts to a Greater Access?

Pharma 52

Pharma Leads Medical Pharmaceutical 52

Pharmaceutical Technology

APRIL 14, 2023

Madrigal Pharmaceuticals’ resmetirom for nonalcoholic steohepatitis (NASH) could be fairly priced at a higher range than Intercept Pharmaceuticals’ obeticholic acid, based on a revised evidence report published by the Institute for Clinical and Economic Review (ICER). Caveats surrounding side effects for obeticholic acid remain.

Side effects 52

Side effects Patients Leads Pharmaceutical 52

Contrarian Sales Techniques

MAY 18, 2023

Pricing Optimally : Pricing the product just right ensured maximum profit. Strategic Pricing : Tweaking prices based on market trends and customer expectations works wonders. More Bang for Your Buck The allure of milking strategy marketing for me was its focus on optimizing resources.

Marketing 52

Marketing Customer Relationship Management Relationship management Management 52

Pharmacy Times

JANUARY 4, 2024

The pattern for the diminished learning curve, associated with elevated amyloid levels, was consistent across 3 memory tasks, with strongest results for recalling digit-signs and groceries prices.

26

26

PM360

APRIL 25, 2023

In many markets around the world, but particularly in Europe, there have always been post-regulatory hurdles for pharmaceutical companies to achieve their price and access ambitions. This benefit, derived from a variety of methodologies, is then related to a price. The examples below are typical of this sort of agreement.

Marketing 97

Marketing Side effects Management Patients 97

Clarify Health

MARCH 17, 2023

One driver of rising healthcare costs is pricing, particularly the pricing of hospital services, which have been notoriously difficult to see in advance of treatment, and even more difficult to compare across providers and networks. Approximately 4.3

Healthcare 52

Healthcare Healthcare Competition Networking 52

pharmaphorum

JANUARY 9, 2023

Eisai and Biogen’s Alzheimer’s therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from the FDA on Friday. Aduhelm was launched at $56,000 per year, before a backlash prompted Biogen to slash it to $28,000.

FDA 93

FDA Physicians Patients Sales 93

PM360

APRIL 7, 2023

The offering provides Amazon Prime members with a $5 monthly add-on to their existing subscription where they can receive “eligible medications” at “one low price.” Simplicity seems to be the aim here, by providing a fixed monthly price consumers don’t need to compare pharmacy prices or discern their insurance copay.

Marketing 52

Marketing Prescription Insurance Retail 52

Clarivate

OCTOBER 25, 2023

The first 10 Medicare Part D drugs chosen for price negotiation by the Centers for Medicare & Medicaid Service treat a wide swath of conditions impacting seniors. Here CMS could realize the biggest impact, since a lower negotiated price should translate to lower coinsurance.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

pharmaphorum

SEPTEMBER 21, 2022

Approval of the first-in-class TSLP inhibitor wasn’t considered a shoo-in, as Tezspire failed one of its two pivotal phase 3 trials, but the Commission and FDA have concluded that the totality of the data – which also included a positive phase 2b study – was enough to show efficacy and safety.

Sales 108

Sales Biopharma Medicine Patients 108

Clarify Health

OCTOBER 15, 2020

Removal of the Physician Group Practice (PGP) Offset Changes: Physician Group target price will be equal to the Hospital target price, and will no longer be adjusted based on PGP historical performance against peers. How have my target prices changed over the past 3 years?

Physicians 52

Physicians Management Leads Patients 52

Pharmaceutical Technology

JULY 21, 2022

Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. Drug pricing and gouging. Inflated drug prices are a subject of intense scrutiny and debate. Access to medication.

Government 52

Government Healthcare Healthcare Pharma 52